Andrea Vereda

TL;DR: Treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose‐limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo, in this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut.

TL;DR: In this article, the clinical and immunologic characteristics of patients with peanut allergy from three countries (Spain, the United States, and Sweden) using a molecular component diagnostic approach were analyzed, and the results showed that Spanish and Swedish patients were more often sensitized to the lipid transfer protein rAra h 9 (60.0% to 42.0%), and typically had peanut allergy after becoming allergic to other plant-derived foods.

TL;DR: AR101 oral immunotherapy treatment led to rapid desensitisation to peanut protein, with a predictable safety profile that improved with treatment, and an associated improvement in self-reported and caregiver-reported food allergy-related quality of life.

TL;DR: Results showed relevant and significant differences between both groups of pollen-allergic patients depending on whether or not they suffered from plant-derived food allergy.

TL;DR: An 11S globulin storage protein has been isolated and identified as a novel major allergen of mustard seeds, belonging to the Cupin super family.